Aflibercept

證據等級: L5

預測適應症: 1 個

Aflibercept: From Neovascular AMD to Esotropia

One-Sentence Summary

Aflibercept is an anti-VEGF fusion protein (VEGF Trap), best known for treating neovascular (wet) age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. The TxGNN model predicts it may also be effective for Esotropia (inward ocular deviation / strabismus). Currently, there are 0 clinical trials and 0 publications directly supporting this specific repurposing direction.

Quick Overview

Item	Content
Original Indication	No records in regulatory database (Neovascular AMD / DME based on known drug profile)
Predicted New Indication	Esotropia
TxGNN Prediction Score	99.38%
Evidence Level	L5
Market Status	✗ Not Marketed (per regulatory query)
Number of NDAs	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the provided evidence pack. Based on known pharmacological information, aflibercept is a recombinant fusion protein (VEGF Trap) comprising the VEGF-binding domains of VEGFR-1 and VEGFR-2, fused to the Fc portion of human IgG1. It binds VEGF-A, VEGF-B, and placental growth factor (PlGF) with higher affinity than either native receptor, blocking downstream signalling and inhibiting pathological angiogenesis and vascular hyper-permeability. Its efficacy in neovascular retinal diseases has been validated across multiple pivotal Phase 3 trials.

Esotropia is a form of strabismus in which one or both eyes deviate medially. Its aetiology spans accommodative imbalance, high myopia, and sensorimotor fusion disruption. A potential mechanistic bridge lies in the VEGF pathway’s role in ocular tissue remodelling and fibrosis: anti-VEGF agents have been explored as surgical adjuncts in strabismus procedures to reduce post-operative scarring around extraocular muscles and Tenon’s capsule, potentially improving alignment durability and reducing recurrence rates.

High-myopia–associated esotropia represents a further point of contact, as progressive axial elongation is accompanied by posterior-segment vascular changes where VEGF inhibition may have biological relevance. The TxGNN knowledge graph most likely identified this shared ophthalmological domain — vascular and connective-tissue biology within the eye — as the basis for its high-confidence prediction. However, without dedicated preclinical or clinical studies, the applicability of aflibercept to esotropia remains speculative.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

No licensing records were returned for aflibercept by the regulatory database query (query date: 2026-03-24). This is likely a database coverage gap rather than an indication of true non-approval: aflibercept (Eylea®) holds FDA approval in the United States for neovascular AMD, macular edema following CRVO and BRVO, diabetic macular edema, and diabetic retinopathy. A full regulatory verification against the FDA Orange Book is recommended as a next step.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN model assigns a very high prediction score (99.38%), there is currently no clinical trial, observational study, or published literature to support the use of aflibercept in esotropia. An L5 evidence level — model prediction only — is insufficient to proceed to clinical evaluation without at least preclinical mechanistic corroboration.

To proceed, the following is needed:

Mechanistic studies: Identify whether VEGF inhibition demonstrably affects extraocular muscle fibrosis, connective tissue remodelling, or accommodative tone in esotropia models (addresses DG002 — MOA gap)
Literature sweep: Broaden search to include anti-VEGF agents as strabismus surgery adjuncts, or VEGF pathway involvement in paediatric/adult esotropia — current PubMed query returned 0 results but broader MeSH terms may yield relevant results
Safety review: Obtain and parse the full prescribing information to complete S1 safety assessment (DG001 — currently a blocking gap)
Regulatory verification: Confirm US FDA approval status via the Orange Book to establish a proper regulatory baseline for the repurposing dossier
Route-of-administration assessment: Aflibercept is administered by intravitreal injection; confirm whether the same route would be appropriate for an esotropia indication or whether an alternative formulation would be required

This report is generated for research reference purposes only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.